Brief: Lineage, Cancer Research UK Report Completion of Patient Enrollment in Study of VAC2 for Treatment of Non-small Cell Lung Cancer
13/04/2022 13:06
April 13 (Reuters) - Lineage Cell Therapeutics Inc LCTX.A :
* LINEAGE AND CANCER RESEARCH UK ANNOUNCE COMPLETION OF
PATIENT
ENROLLMENT IN PHASE 1 CLINICAL STUDY OF VAC2 FOR THE TREATMENT
OF NON-SMALL CELL LUNG CANCER
Source text for Eikon: ID:nBwbqBlfma
Further company coverage: LCTX.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lineage Cell Therapeutics
See all newsLineage Cell Therapeutics Q2 revenue falls but posts profit
Brief: Lineage Cell Therapeutics Q2 Income From Operations USD -8.923 Million
Lineage Cell Therapeutics Q1 net loss widens as expenses rise
Lineage Cell Q4 revenue rises on Genentech collaboration
Brief: Lineage Cell Therapeutics FY Income From Operations USD -36.619 Million